LEGN
Legend Biotech Corporation
NASDAQ · Healthcare · Biotechnology · US
$21.57
−0.83%Aug 11, 2026, 13:05 UTC
Legend Biotech reported second-quarter 2026 results, achieving its first quarter of company-wide profitability on both IFRS and adjusted basis, with continued global growth for CARVYKTI.
Aug 11, 2026, 12:00 UTC
K2 Therapeutics appointed Huang Ying, former CEO of Legend Biotech, as its new CEO.
Source:Jul 27, 2026, 10:00 UTC
Ying Huang stepped down as Chief Executive Officer and board member of Legend Biotech, effective July 24, 2026.
Jun 17, 2026, 20:29 UTC
Legend Biotech Corporation commenced an underwritten public offering of $225 million of American Depositary Shares.
Jun 14, 2026, 07:15 UTC
Legend Biotech announced first clinical proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell Non-Hodgkin Lymphoma.
Jun 1, 2026, 14:00 UTC
Legend Biotech presented first-in-human clinical data for its investigational CAR-T cell therapy LB2102 at ASCO 2026.
Source:Jun 1, 2026, 02:03 UTC
Legend Biotech held an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma.
Source: